Document Detail


Treatment and prevention of vitamin D insufficiency in cystic fibrosis patients: comparative efficacy of ergocalciferol, cholecalciferol, and UV light.
MedLine Citation:
PMID:  19336509     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The optimal treatment for correcting or preventing vitamin D insufficiency in cystic fibrosis (CF) patients has not been established. OBJECTIVE: The aim of the study was to assess the relative efficacy of three modes of vitamin D therapy: cholecalciferol (D3), ergocalciferol (D2), and UV light in raising or maintaining 25(OH)D levels above 30 ng/ml. DESIGN: Thirty adult CF subjects with vitamin D insufficiency were randomized into one of three treatment arms: D3, D2, or UV light. Subjects randomized to D3 or D2 ingested 50,000 IU of vitamin D weekly, and those randomized to UV exposed their skin to UV light from a lamp five times a week. Serum was collected for 25(OH)D and PTH at baseline and at 12 wk. RESULTS: Treatment with D3 and D2 raised 25(OH)D levels significantly, from a mean of 21.2 +/- 10.18 to 47.1 +/- 20.5 ng/ml (P < 0.001) and 24.4 +/- 10.3 to 32.7+/- 9.7 ng/ml (P = 0.01), with 100% and 60% reaching 25(OH)D levels above 30 ng/ml, respectively. Treatment with UV did not raise 25(OH)D levels significantly; however, only 55% of subjects were adherent with UV therapy. CONCLUSION: This study demonstrates that CF subjects are able to achieve or maintain optimal vitamin D status (>30 ng/ml) with two oral regimens of either D3 or D2 treatment, the former being more efficacious. A confounding variable for this observation is the fact that the D3 and D2 capsules contained different carriers, powder-based vs. oil-based, respectively. UV therapy did not alter vitamin D status, possibly due to poor adherence to UV therapy.
Authors:
Natasha B Khazai; Suzanne E Judd; Leo Jeng; Linda L Wolfenden; Arlene Stecenko; Thomas R Ziegler; Vin Tangpricha
Related Documents :
11260019 - Mycophenolate mofetil as a systemic antipsoriatic agent: positive experience in 11 pati...
7016629 - A double-blind trial of budesonide ointment and betamethasone-17-valerate ointment in p...
20001319 - Efficacy of topical aminolevulinic acid photodynamic therapy for the treatment of verru...
11069469 - Imiquimod: a novel treatment for lentigo maligna.
14961909 - Psoriasis induced by topical imiquimod.
16198779 - Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a random...
20513989 - Early results of total knee arthroplasty performed through the midvastus approach.
25204509 - Continuous administration of landiolol reduced qt dispersion in postoperative patients.
24193229 - Impact of inhaled corticosteroid treatment on 15-year longitudinal respiratory function...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2009-03-31
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  94     ISSN:  1945-7197     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-04     Completed Date:  2009-07-02     Revised Date:  2010-09-22    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2037-43     Citation Subset:  AIM; IM    
Affiliation:
Division of Endocrinology, Diabetes, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Cholecalciferol / adverse effects,  blood,  therapeutic use*
Cystic Fibrosis / therapy*
Ergocalciferols / adverse effects,  blood,  therapeutic use*
Female
Humans
Hydroxycholecalciferols / blood
Male
Middle Aged
Parathyroid Hormone / blood
Patient Compliance
Ultraviolet Therapy* / adverse effects
Vitamin D Deficiency / blood,  prevention & control*,  therapy*
Young Adult
Grant Support
ID/Acronym/Agency:
K23AR054334/AR/NIAMS NIH HHS
Chemical
Reg. No./Substance:
0/Ergocalciferols; 0/Hydroxycholecalciferols; 0/Parathyroid Hormone; 67-97-0/Cholecalciferol
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Next Document:  Influence of Growth Hormone Receptor d3 and Full-Length Isoforms on Biochemical Treatment Outcomes i...